A study to determine disease activity and COVID antibody responses in patients with immune mediated inflammatory disease treated with homologous or heterogeneous COVID vaccines
Latest Information Update: 29 Jun 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 29 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism